DE3588205T2 - Verwendung von Adenosin zur Herstellung eines Arzneimittels für kontinuierliche Intravenöse Infusion an menschlichen Patienten - Google Patents
Verwendung von Adenosin zur Herstellung eines Arzneimittels für kontinuierliche Intravenöse Infusion an menschlichen PatientenInfo
- Publication number
- DE3588205T2 DE3588205T2 DE3588205T DE3588205T DE3588205T2 DE 3588205 T2 DE3588205 T2 DE 3588205T2 DE 3588205 T DE3588205 T DE 3588205T DE 3588205 T DE3588205 T DE 3588205T DE 3588205 T2 DE3588205 T2 DE 3588205T2
- Authority
- DE
- Germany
- Prior art keywords
- adenosine
- medicament
- administered
- infusion
- coronary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title claims abstract description 136
- 239000002126 C01EB10 - Adenosine Substances 0.000 title claims abstract description 68
- 229960005305 adenosine Drugs 0.000 title claims abstract description 68
- 238000001802 infusion Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 238000001990 intravenous administration Methods 0.000 title abstract description 10
- 230000017531 blood circulation Effects 0.000 claims abstract description 13
- 230000001965 increasing effect Effects 0.000 claims abstract description 11
- 230000024883 vasodilation Effects 0.000 claims abstract description 10
- 210000004351 coronary vessel Anatomy 0.000 claims abstract description 4
- 230000037396 body weight Effects 0.000 claims description 6
- 230000002107 myocardial effect Effects 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 230000036772 blood pressure Effects 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 abstract description 6
- 210000002216 heart Anatomy 0.000 abstract description 4
- 230000000004 hemodynamic effect Effects 0.000 abstract description 3
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 8
- 230000004087 circulation Effects 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 230000000304 vasodilatating effect Effects 0.000 description 5
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 4
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 4
- 229960002768 dipyridamole Drugs 0.000 description 4
- 229960002460 nitroprusside Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940124549 vasodilator Drugs 0.000 description 4
- 239000003071 vasodilator agent Substances 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 102000015427 Angiotensins Human genes 0.000 description 3
- 108010064733 Angiotensins Proteins 0.000 description 3
- 206010003671 Atrioventricular Block Diseases 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000010271 Heart Block Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229940083618 sodium nitroprusside Drugs 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 229960002474 hydralazine Drugs 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77951685A | 1985-09-24 | 1985-09-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3588205D1 DE3588205D1 (de) | 1999-03-11 |
| DE3588205T2 true DE3588205T2 (de) | 1999-06-02 |
Family
ID=25116698
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19853590855 Withdrawn DE3590855T1 (enExample) | 1985-09-24 | 1985-10-29 | |
| DE3588205T Expired - Lifetime DE3588205T2 (de) | 1985-09-24 | 1985-10-29 | Verwendung von Adenosin zur Herstellung eines Arzneimittels für kontinuierliche Intravenöse Infusion an menschlichen Patienten |
| DE3586993T Expired - Fee Related DE3586993T3 (de) | 1985-09-24 | 1985-10-29 | Kontinuierliche intravenöse infusion von adenosin an menschlichen patienten, einheitsdosierungsform von adenosin und dessen verwendung bei der herstellung von arzneimitteln. |
| DE1999175044 Active DE19975044I2 (de) | 1985-09-24 | 1985-10-29 | Verwendung von Adenosin zur Herstellung eines Arzneimittels f}r kontinuierliche Intraven¦se Infusionan menschlichen Patienten |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19853590855 Withdrawn DE3590855T1 (enExample) | 1985-09-24 | 1985-10-29 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3586993T Expired - Fee Related DE3586993T3 (de) | 1985-09-24 | 1985-10-29 | Kontinuierliche intravenöse infusion von adenosin an menschlichen patienten, einheitsdosierungsform von adenosin und dessen verwendung bei der herstellung von arzneimitteln. |
| DE1999175044 Active DE19975044I2 (de) | 1985-09-24 | 1985-10-29 | Verwendung von Adenosin zur Herstellung eines Arzneimittels f}r kontinuierliche Intraven¦se Infusionan menschlichen Patienten |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP0275249B2 (enExample) |
| JP (1) | JP2535504B2 (enExample) |
| AT (2) | ATE84419T1 (enExample) |
| AU (1) | AU613304B2 (enExample) |
| CA (1) | CA1301652C (enExample) |
| DE (4) | DE3590855T1 (enExample) |
| DK (1) | DK253187A (enExample) |
| NZ (1) | NZ217592A (enExample) |
| WO (1) | WO1987001593A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3782427T2 (de) * | 1986-10-06 | 1996-07-18 | Univ Virginia | Verwendung einer adenosin, hypoxanthin und ribose enthaltender lösung zur schonung des herzens während chirurgischer eingriffe. |
| US5070877A (en) * | 1988-08-11 | 1991-12-10 | Medco Research, Inc. | Novel method of myocardial imaging |
| US6004945A (en) * | 1990-05-10 | 1999-12-21 | Fukunaga; Atsuo F. | Use of adenosine compounds to relieve pain |
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| US5256398A (en) * | 1990-11-08 | 1993-10-26 | Whitby Research, Inc. | Composition for determining viability of tissue |
| US5681278A (en) * | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
| EP2627369B1 (en) | 2010-10-15 | 2022-01-12 | SeaStar Medical, Inc. | Cytopheresic cartridge and use thereof |
| WO2013077283A1 (ja) * | 2011-11-21 | 2013-05-30 | 国立大学法人大阪大学 | 腎動脈アブレーション用のカテーテルおよびシステム |
| EP4194024A1 (en) | 2012-01-09 | 2023-06-14 | SeaStar Medical, Inc. | Cartridge and method for increasing myocardial function |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845205A (en) * | 1970-06-04 | 1974-10-29 | Univ Sydney | 2-loweralkylthioadenosines |
| FR2129833B1 (enExample) * | 1971-03-16 | 1974-08-02 | Cerm Cent Europ Rech Mauvernay | |
| ZA7467B (en) * | 1973-01-16 | 1974-11-27 | J Voorhees | Compositions and treatment of proliferative skin diseases with b2 agonists |
| DE3133925A1 (de) * | 1981-08-27 | 1983-03-17 | A. Nattermann & Cie GmbH, 5000 Köln | Arzneimittel zur behandlung von hypertonie |
| DE3406533A1 (de) * | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten |
-
1985
- 1985-10-29 AT AT85905544T patent/ATE84419T1/de not_active IP Right Cessation
- 1985-10-29 DE DE19853590855 patent/DE3590855T1/de not_active Withdrawn
- 1985-10-29 JP JP60504950A patent/JP2535504B2/ja not_active Expired - Lifetime
- 1985-10-29 DE DE3588205T patent/DE3588205T2/de not_active Expired - Lifetime
- 1985-10-29 EP EP85905544A patent/EP0275249B2/en not_active Expired - Lifetime
- 1985-10-29 WO PCT/SE1985/000423 patent/WO1987001593A1/en not_active Ceased
- 1985-10-29 EP EP92201323A patent/EP0506205B1/en not_active Expired - Lifetime
- 1985-10-29 DE DE3586993T patent/DE3586993T3/de not_active Expired - Fee Related
- 1985-10-29 DE DE1999175044 patent/DE19975044I2/de active Active
- 1985-10-29 AU AU50655/85A patent/AU613304B2/en not_active Expired
- 1985-10-29 AT AT92201323T patent/ATE176154T1/de not_active IP Right Cessation
-
1986
- 1986-09-16 NZ NZ217592A patent/NZ217592A/xx unknown
- 1986-09-23 CA CA000518809A patent/CA1301652C/en not_active Expired - Lifetime
-
1987
- 1987-05-19 DK DK253187A patent/DK253187A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63501497A (ja) | 1988-06-09 |
| EP0506205A1 (en) | 1992-09-30 |
| DE3590855T1 (enExample) | 1988-08-25 |
| CA1301652C (en) | 1992-05-26 |
| DE3586993D1 (de) | 1993-02-25 |
| EP0275249A1 (en) | 1988-07-27 |
| NZ217592A (en) | 1990-10-26 |
| WO1987001593A1 (en) | 1987-03-26 |
| DE3586993T3 (de) | 1998-03-19 |
| AU613304B2 (en) | 1991-08-01 |
| DE3586993T2 (de) | 1993-04-29 |
| DK253187D0 (da) | 1987-05-19 |
| EP0506205B1 (en) | 1999-01-27 |
| ATE84419T1 (de) | 1993-01-15 |
| DE19975044I2 (de) | 2006-02-02 |
| DE3588205D1 (de) | 1999-03-11 |
| AU5065585A (en) | 1987-04-07 |
| EP0275249B1 (en) | 1993-01-13 |
| DK253187A (da) | 1987-05-19 |
| JP2535504B2 (ja) | 1996-09-18 |
| EP0275249B2 (en) | 1997-12-17 |
| ATE176154T1 (de) | 1999-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533940T2 (de) | Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren | |
| DE69722401T2 (de) | Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods | |
| DE69434416T2 (de) | Präparate auf purinbasis | |
| DE60008352T2 (de) | Pyridoxin-derivate in der behandlung von kardiovaskulären beschwerden | |
| US5231086A (en) | Continuous administration adenosine to increase myocardial blood flow | |
| DE69232565T2 (de) | Verfahren zur behandlung von lungenerkrankungen mit uridin-triphosphaten | |
| DE69938499T2 (de) | Endogene stickstoffoxidsynthese unter bedingungen von niedrigem sauerstoffpartialdruck | |
| DE69628025T2 (de) | Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus | |
| US5449665A (en) | Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty | |
| DE69827126T2 (de) | Verwendung von hypothalamus-hemmfaktor zur behandlung von ischämischen herzstörungen | |
| DE602004002585T2 (de) | Laktathaltige pharmazeutische Zusammensetzung und deren Verwendungen | |
| DE68920656T2 (de) | Verwendung vpn Adenosin-5'-phosphate in der Behandlung von Krebscachexia. | |
| DE3505359A1 (de) | Arzneimittel zur behandlung von akuter, myocardialer ischaemie | |
| DE69835824T2 (de) | Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin | |
| DE3588205T2 (de) | Verwendung von Adenosin zur Herstellung eines Arzneimittels für kontinuierliche Intravenöse Infusion an menschlichen Patienten | |
| EP0108820B1 (de) | Infusionslösungen zur Herztherapie | |
| EP0363671A2 (de) | Verwendung von ACE-Inhibitoren gegen Neointimabildung nach Gefässverletzung | |
| DE68907976T2 (de) | Verwendung eines Thromboxan-A2-Rezeptorantagonist zur Herstellung eines Arzeneimittels zur Behandlung pulmonarer Hypertonie, die durch Protamin-induzierte Neutralisation von Heparin verursacht wird. | |
| DE3880943T2 (de) | Verwendung von thromboxan-a2-antagonisten zur herstellung eines arzneimittels zur wiederherstellung von post-ischaemischer myokard-dysfunktion. | |
| DE60207824T2 (de) | Cytidin-diphosphocholin gegen diabetische neuropathie | |
| DE69127541T2 (de) | Pharmazeutische zusammensetzung | |
| DE69808270T2 (de) | Verbesserte darreichung von antikrebsmittel an feste tumore mittels primer-verbindungen | |
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| Van Wezel et al. | Comparison of nitroglycerine, verapamil and nifedipine in the management of arterial pressure during coronary artery surgery | |
| DE69421174T2 (de) | Verwendung von adenosin zur herstellung eines arzneimittels zur behandlung entzüdlicher reaktionen der lunge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| V448 | Application of spc |
Free format text: PRODUCT NAME: ADENOSIN; REGISTRATION NO/DATE: 40307.00.00, 19970721 Spc suppl protection certif: 199 75 044 Filing date: 19990629 |
|
| V457 | Spc granted |
Free format text: PRODUCT NAME: ADENOSIN; REGISTRATION NO/DATE: 40307.00.00, 19970721 Spc suppl protection certif: 199 75 044 Filing date: 19990629 |
|
| V484 | Delivery of the decision of grant |
Free format text: PRODUCT NAME: ADENOSIN; REGISTRATION NO/DATE: 40307.00.00, 19970721 Spc suppl protection certif: 199 75 044 Filing date: 19990629 |
|
| V464 | Spc expired |
Free format text: PRODUCT NAME: ADENOSIN; REGISTRATION NO/DATE: 40307.00.00, 19970721 Spc suppl protection certif: 199 75 044 Filing date: 19990629 |